TwinBeech Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.23M Buy
+42,428
New +$1.12M 0.29% 107
2024
Q2
– Sell
-33,604
Closed -$95.4K – 518
2024
Q1
$95.4K Sell
33,604
-132,840
-80% -$1.74M ﹤0.01% 508
2023
Q4
$2.45M Buy
166,444
+84,860
+104% +$1.3M 0.04% 373
2023
Q3
$1.49M Sell
81,584
-74,464
-48% -$1.57M 0.03% 443
2023
Q2
$3.37M Buy
156,048
+24,276
+18% +$656K 0.07% 315
2023
Q1
$3.87M Buy
+131,772
New +$4.58M 0.08% 278

Other funds holding AMLX

TwinBeech Capital's AMLX Position: Q3 2026 in Review

TwinBeech Capital opened a new position in Amylyx Pharmaceuticals (AMLX) in Q3 2026: 42,428 shares worth $1.23M. The stake represents 0.29% of the portfolio and ranks #107 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in AMLX as recently as Q1 2024.

TwinBeech Capital first reported a position in AMLX in Q1 2023 and has held it in 6 quarters since. The position peaked at $3.87M in Q1 2023. 230 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • TwinBeech Capital held 42,428 shares of Amylyx Pharmaceuticals worth $1.23M as of Q3 2026.
  • Amylyx Pharmaceuticals was a new TwinBeech Capital position in Q3 2026.
  • Amylyx Pharmaceuticals made up 0.29% of TwinBeech Capital's portfolio in Q3 2026, its #107 holding.
  • TwinBeech Capital first reported a position in Amylyx Pharmaceuticals in Q1 2023 and has held it in 6 quarters since.
  • TwinBeech Capital's Amylyx Pharmaceuticals position peaked at $3.87M in Q1 2023.
  • 230 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on TwinBeech Capital's 13F filing for Q3 2026, filed 16 Nov 2026.